Clinical Trials Logo

AML, Adult clinical trials

View clinical trials related to AML, Adult.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05177731 Active, not recruiting - Chemotherapy Effect Clinical Trials

Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML

Start date: March 1, 2022
Phase: Phase 3
Study type: Interventional

This research is being done to assess the therapeutic efficacy and safety of a promising (venetoclax and decitabine) versus conventional "7+3"chemotherapy in induction young patients with acute myeloid leukemia. This study involves the following: Venetoclax and decitabine (investigational combination) Cytarabine and idarubicin (per standard of care)

NCT ID: NCT04755244 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)

Start date: May 5, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with venetoclax and azacitidine for the treatment of patients with acute myeloid leukemia (AML).

NCT ID: NCT04749355 Active, not recruiting - Clinical trials for Refractory Acute Myeloid Leukemia

Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS

Start date: November 14, 2021
Phase: Phase 2
Study type: Interventional

An open label multi center study to assess the safety and efficacy of BST-236 as single agent in adult patients unfit for standard therapy with Acute Myeloid Leukemia (AML) or higher-risk (HR) Myelodysplastic Syndromes (MDS) who fail to respond or relapsed following first line therapy. Approximately 20 adult patients with relapsed and/or refractory AML and approximately 20 adult patients with relapsed and/or refractory HR MDS, will be enrolled into the study. Patients will be treated with 1-2 induction courses and 2-4 maintenance courses. All patients will be followed for 1 year in the study and additional 1 year post study follow-up.

NCT ID: NCT04623944 Active, not recruiting - MDS Clinical Trials

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Start date: September 21, 2020
Phase: Phase 1
Study type: Interventional

This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very high risk relapsed/refractory MDS.

NCT ID: NCT04512105 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia

Start date: December 2, 2020
Phase: Phase 1
Study type: Interventional

This is a phase I, dose-escalation, open-label clinical trial determining the safety and tolerability of adding Pitavastatin to Venetoclax in subjects with chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML). These are subjects who are newly diagnosed subjects with AML who are ineligible for intensive induction chemotherapy, relapsed/refractory CLL or newly diagnosed CLL.

NCT ID: NCT04380441 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Quality of Life Model for Older Patients With AML

Start date: July 8, 2020
Phase:
Study type: Observational

The purpose of this study is to describe the differences in quality of life (QOL) among newly diagnosed patients diagnosed with acute myeloid leukemia (AML) to help design a patient decision-making QOL model for aligning patients' choice of treatment with what matters the most to them.